Clinical Trial: Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

Brief Summary: The long-term goal of this study is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease. The goal of this study is to learn about the safety of Zoledronic Acid in persons with sickle cell disease who experience chronic pain requiring medical treatment or use of narcotics.

Detailed Summary:
Sponsor: Virginia Commonwealth University

Current Primary Outcome: The long-term goal of this project is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease. [ Time Frame: Within 2 weeks of study drug administration and then every month for approximately 1 year ]

Original Primary Outcome: Same as current

Current Secondary Outcome: The specific purposes of this study are to learn if Zoledronic Acid has serious side effects for subjects with sickle cell disease and to study the effects of Zoledronic acid in subjects with sickle cell disease. [ Time Frame: Two weeks after study drug administration and then every month for approximately 1 year ]

Original Secondary Outcome: Same as current

Information By: Virginia Commonwealth University

Dates:
Date Received: March 14, 2008
Date Started: June 2007
Date Completion:
Last Updated: November 10, 2011
Last Verified: November 2011